Gilead Sciences to Acquire PepStar’s Oral IL-23R Inhibitor Program for $1.275 Billion Gilead Sciences, Inc. has entered into a definitive agreement to acquire an oral interleukin-23 receptor (IL-23R) inhibitor program,…
Drug Farm Reports Positive Preclinical Findings Showing DF-003 Reduces Kidney Inflammation and Fibrosis Drug Farm has announced positive preclinical findings demonstrating that DF-003, its proprietary, first-in-class oral ALPK1 inhibitor, reduced…
Nutromics Demonstrates World-First Real-Time Creatinine Monitoring in Humans Using DNA-Based Wearable Sensors Nutromics has presented what it describes as world-first real-time measurements of creatinine in humans using DNA-based sensors, marking…
Future Health and Bridge for Billions Launch Global Entrepreneurship Programme to Support Health Innovation in Emerging Markets Future Health – A Global Initiative by Abu Dhabi, in collaboration with Bridge…
Merck and Moderna Report Positive Phase 3 INTerpath-001 Results for Intismeran Autogene Plus KEYTRUDA in Resected Melanoma Merck, known as MSD outside the United States and Canada, and Moderna, Inc.…
Future Health and Bridge for Billions Launch Programme to Scale Health Innovation Across Emerging Markets Future Health, a global initiative by Abu Dhabi, is partnering with Bridge for Billions to…
Immunis Wins National Academy of Medicine Grand Prize for IMM01-STEM Healthy Longevity Innovation Immunis, Inc., a clinical-stage biotechnology company developing first-in-class multi-active biologics for muscle health and healthy aging, has…
ViiV Healthcare Reports Five-Year Real-World Evidence Supporting Long-Term Cabenuva Effectiveness in HIV Treatment ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, has…
Edwards Lifesciences Receives FDA Approval for PASCAL Precision System for Tricuspid Valve Repair Edwards Lifesciences Corporation (NYSE: EW), a global developer of patient-focused innovations for structural heart disease, has announced…
TG Therapeutics Highlights Seven-Year BRIUMVI Data, Positive Phase 3 ENHANCE Results and Progress in Progressive MS Research at MSToronto2026 TG Therapeutics, Inc. (NASDAQ: TGTX) has announced a series of updated…
HeartBeam Completes Enrollment in 486-Patient HEADSTART-ACS Study Ahead of Schedule to Advance 3D ECG Heart Attack Detection Technology HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac…
AngioDynamics Reports Positive DIRECT Study Results for NanoKnife IRE in Pancreatic Cancer and Announces New CPT Code for 2027 AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring…